European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"Atypical [18F]FDG avidity in ALK-positive anaplastic large cell lymphoma: diagnostic and monitoring potential of [18F]FAPI PET/CT.","authors":"Xiaorui Chen,Sun Yu,Xinhui Su,Jingsong He,Peipei Wang","doi":"10.1007/s00259-025-07360-6","DOIUrl":"https://doi.org/10.1007/s00259-025-07360-6","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"6 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144136842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel framework for response evaluation criteria in grade 1/2 neuroendocrine tumors (RECIN) following [177Lu]Lu-DOTATATE therapy: post-hoc analysis of the phase 2 LuCAP trial.","authors":"Swayamjeet Satapathy,Piyush Aggarwal,Ashwani Sood,Kunal R Chandekar,Chandan K Das,Rajesh Gupta,Divya Khosla,Namrata Das,Rakesh Kapoor,Rajender Kumar,Harmandeep Singh,Bhagwant R Mittal","doi":"10.1007/s00259-025-07351-7","DOIUrl":"https://doi.org/10.1007/s00259-025-07351-7","url":null,"abstract":"PURPOSETreatment response assessment in grade 1/2 neuroendocrine tumors (NETs) has been a key challenge due to their indolent nature. Here, we propose the novel response evaluation criteria with [68Ga]Ga-somatostatin analogue (SSA)-PET/CT in grade 1/2 NETs (RECIN) following [177Lu]Lu-DOTATATE therapy and evaluate its survival impact vis-à-vis conventional radiographic response assessment.METHODSThis was a post-hoc analysis of the phase 2 LuCAP trial, wherein somatostatin receptor-positive, advanced grade 1/2 gastroenteropancreatic NET patients were treated with [177Lu]Lu-DOTATATE ± capecitabine. Tumor response assessment was done with serial [68Ga]Ga-DOTANOC-PET/CECT. Up to five target lesions were evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) for radiographic response. Summed SULpeak of maximum five hottest lesions were evaluated for molecular response. Associations with progression-free survival (PFS) were evaluated using hazard ratios (HRs) and their 95% confidence intervals (95%CIs) along with Harrell's C-index.RESULTSSeventy-two patients were included with 23/72 (32%) patients achieving RECIST-partial response (PR). The novel RECIN-PR was defined as ≥ 25% decrease in summed SULpeak or conventional RECIST-PR with no signs of radiographic progression. Based on this, 40/72 (56%) patients achieved RECIN-PR. In particular, of the 42 patients with RECIST-stable disease, 17 (40%) had RECIN-PR. RECIN-PR was associated with significantly better PFS (HR: 0.33, 95%CI: 0.15-0.76; C-index: 0.67) and had better predictive ability compared to RECIST-PR (HR: 0.52, 95%CI: 0.21-1.29; C-index: 0.60).CONCLUSIONIn advanced grade 1/2 NETs treated with [177Lu]Lu-DOTATATE, [68Ga]Ga-SSA-PET/CT-based novel RECIN framework proved superior to conventional radiographic response assessment in terms of early response detection in indolent disease and better predictive ability.CLINICAL TRIAL REGISTRATIONClinical Trials Registry-India, CTRI/2020/01/022636.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"15 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144136844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diffuse uptake in the subcutaneous tissue on 18F-Florbetapir PET/CT.","authors":"Zhenchun Xu,Qiaoqiao Shu,Yue Feng,YongZeng Fan,Xiaojiao Xiang","doi":"10.1007/s00259-025-07322-y","DOIUrl":"https://doi.org/10.1007/s00259-025-07322-y","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"23 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144136841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-in-human administration of [61Cu]Cu-NODAGA-LM3 and head-to-head comparison with [68Ga]Ga-DOTA-TOC PET/CT as part of the phase I/II COPPER PET in NET study","authors":"Guillaume P. Nicolas, Manuel Alejandre Lafont, Lisa McDougall, Felix Kaul, Alin Chirindel, Wolfgang Weber, Angela Llmazares, Anass Johayem, Markus Baier, Nicole Schubert, Francesco De Rose, Leila Jaafar-Thiel, Andreas Bauman, Melpomeni Fani, Damian Wild","doi":"10.1007/s00259-025-07301-3","DOIUrl":"https://doi.org/10.1007/s00259-025-07301-3","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"19 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144130089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of locoregional invasiveness of early lung adenocarcinoma manifesting as ground-glass nodules via [68Ga]Ga-FAPI-46 PET/CT imaging","authors":"Dan Ruan, Sien Shi, Weixi Guo, Yizhen Pang, Lingyu Yu, Jiayu Cai, Zhenyu Wu, Hua Wu, Long Sun, Liang Zhao, Haojun Chen","doi":"10.1007/s00259-025-07361-5","DOIUrl":"https://doi.org/10.1007/s00259-025-07361-5","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Accurate differentiation of the histologic invasiveness of early-stage lung adenocarcinoma is crucial for determining surgical strategies. This study aimed to investigate the potential of [<sup>68</sup>Ga]Ga-FAPI-46 PET/CT in assessing the invasiveness of early lung adenocarcinoma presenting as ground-glass nodules (GGNs) and identifying imaging features with strong predictive potential.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>This prospective study (NCT04588064) was conducted between July 2020 and July 2022, focusing on GGNs that were confirmed postoperatively to be either invasive adenocarcinoma (IAC), minimally invasive adenocarcinoma (MIA), or precursor glandular lesions (PGL). A total of 45 patients with 53 pulmonary GGNs were included in the study: 19 patients with GGNs associated with PGL-MIA and 34 with IAC. Lung nodules were segmented using the Segment Anything Model in Medical Images (MedSAM) and the PET Tumor Segmentation Extension. Clinical characteristics, along with conventional and high-throughput radiomics features from High-resolution CT (HRCT) and PET scans, were analysed. The predictive performance of these features in differentiating between PGL or MIA (PGL-MIA) and IAC was assessed using 5-fold cross-validation across six machine learning algorithms. Model validation was performed on an independent external test set (<i>n</i> = 11). The Chi-squared, Fisher’s exact, and DeLong tests were employed to compare the performance of the models.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The maximum standardised uptake value (SUVmax) derived from [<sup>68</sup>Ga]Ga-FAPI-46 PET was identified as an independent predictor of IAC. A cut-off value of 1.82 yielded a sensitivity of 94% (32/34), specificity of 84% (16/19), and an overall accuracy of 91% (48/53) in the training set, while achieving 100% (12/12) accuracy in the external test set. Radiomics-based classification further improved diagnostic performance, achieving a sensitivity of 97% (33/34), specificity of 89% (17/19), accuracy of 94% (50/53), and an area under the receiver operating characteristic curve (AUC) of 0.97 [95% CI: 0.93–1.00]. Compared with the CT-based radiomics model and the PET-based model, the combined PET/CT radiomics model did not show significant improvement in predictive performance. The key predictive feature was [<sup>68</sup>Ga]Ga-FAPI-46 PET log-sigma-7-mm-3D_firstorder_RootMeanSquared.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The SUVmax derived from [<sup>68</sup>Ga]Ga-FAPI-46 PET/CT can effectively differentiate the invasiveness of early-stage lung adenocarcinoma manifesting as GGNs. Integrating high-throughput features from [<sup>68</sup>Ga]Ga-FAPI-46 PET/CT images can considerably enhance classification accuracy.</p><h3 data-test=\"abstract-sub-heading\">Clinical trial registration number</h3><p>NCT04588064; URL: https://clinicaltrials.gov/study/NCT04588064.<","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"60 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144130350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detecting early cardiomyopathy in transthyretin variant carriers: reappraising the diagnostic value of Perugini grade 1 radiotracer uptake on bone scintigraphy.","authors":"H S A Tingen,M Berends,A Tubben,P van der Meer,R H J A Slart,J Bijzet,P A van der Zwaag,C Kimmich,C Knackstedt,F L H Muntinghe,E J Houwerzijl,B P C Hazenberg,H L A Nienhuis","doi":"10.1007/s00259-025-07328-6","DOIUrl":"https://doi.org/10.1007/s00259-025-07328-6","url":null,"abstract":"PURPOSETo determine whether TTRv carriers with Perugini grade 1 cardiac radiotracer uptake on [99mTc]Tc- hydroxydiphosphonate bone scintigraphy have or develop ATTR-CM.METHODSThis retrospective observational study was conducted at the Groningen Amyloidosis Centre of Expertise between April 2012 and June 2023. TTRv carriers with Perugini grade 1 uptake on bone scintigraphy were followed until to June 2024. Data on symptoms, biomarkers, imaging, and biopsies were collected. A descriptive analysis was performed to evaluate whether carriers met the diagnostic criteria for ATTR-CM or 'probable ATTR-CM' at baseline and follow-up.RESULTSOut of 178 TTRv carriers in screening, 12 carriers had Perugini grade 1 cardiac radiotracer uptake on bone scintigraphy. At baseline, 2 carriers met the diagnostic criteria for ATTR-CM and 3 carriers met the criteria for probable ATTR-CM. Of the 7 carriers without (probable) ATTR-CM at baseline, 3 carriers were diagnosed with ATTR-CM during follow-up and 1 carrier developed probable ATTR-CM during follow-up. Three carriers showed signs of cardiomyopathy during follow-up, but did not meet the criteria for (probable) ATTR-CM. One of these cases may have been false-positive due to hydroxychloroquine use.CONCLUSIONOur findings suggest that Perugini grade 1 cardiac radiotracer uptake is an early marker of ATTR-CM in TTRv carriers, potentially enabling earlier diagnosis and intervention.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"137 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144122045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between yttrium-90 glass microspheres specific activity, particle density and treatment outcomes in HCC and mCRC","authors":"Marnix G. E. H. Lam, Etienne Garin, Kirk D. Fowers, Armeen Mahvash, Siddharth A. Padia, Riad Salem","doi":"10.1007/s00259-025-07334-8","DOIUrl":"https://doi.org/10.1007/s00259-025-07334-8","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>To investigate relationships between treatment week, relative to Ytrrium-90 (⁹⁰Y) glass microsphere calibration (i.e., specific activity and particle density), and outcomes for hepatocellular carcinoma (HCC) or colorectal cancer liver metastasis (mCRC).</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Multinational, multicenter study TARGET (retrospective; <i>n</i> = 209 HCC patients) was combined with EPOCH (phase III trial; <i>n</i> = 428 mCRC patients). Efficacy included overall response rate (ORR), overall survival (OS), progression-free survival (PFS), hepatic PFS, and tumour marker response rates. Safety included clinical and laboratory toxicity. Retrospective multicompartment dosimetry, tumour and normal tissue absorbed dose were available for TARGET; single compartment dosimetry was available for EPOCH.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>No efficacy relationship was found relative to treatment week for TARGET or EPOCH. mRECIST ORR in TARGET for weeks 1 and 2 were 74/125 (59.2%) and 55/84 (65.5%), and by RECIST 1.1 in EPOCH were 54/142 (38.0%) and 15/43 (34.9%), respectively (<i>p</i> &gt; 0.05). Median OS for TARGET weeks 1 and 2 were 21.4 and 20.3 months (<i>p</i> = 0.07), and in EPOCH were 14.9 and 16.4 months, respectively (<i>p</i> = 0.37). No difference in the TARGET primary endpoint of hyperbilirubinemia was noted for weeks 1 and 2, odds ratio 0.64, <i>p</i> = 0.59. TARGET ≥ grade 3 device-related adverse events (AEs) for weeks 1 (16.8%) and 2 (26.2%) were not significantly different (<i>p</i> = 0.11). EPOCH rates of ≥ grade 3 asthenia for weeks 1 (9.2%) and 2 (23.3%) were statistically different (<i>p</i> = 0.01).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>No efficacy treatment benefit for week 2 versus week 1 was observed in TARGET or EPOCH, but week 2 treatment trended towards a higher rate and severity of specific AEs.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"133 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radioembolization of hepatocellular carcinoma with 90Y glass microspheres: an earlier administration day unexpectedly improves tumour control probability.","authors":"Matteo Bagnalasta,Stefania Mazzaglia,Maria Chiara De Nile,Chiara Romanò,Giovanna Pitoni,Alice Phillips,Gaetano Amato,Carlo Spreafico,Carlo Morosi,Tommaso Cascella,Alfonso Marchianò,Marianna Maspero,Valentina Bellia,Gianluca Aliberti,Alessandra Alessi,Vincenzo Mazzaferro,Marco Maccauro,Carlo Chiesa","doi":"10.1007/s00259-025-07295-y","DOIUrl":"https://doi.org/10.1007/s00259-025-07295-y","url":null,"abstract":"PURPOSE90Y glass microspheres have a shelf life of 12 days from the calibration date, allowing flexible administration after a variable decay interval. For a fixed intended activity, a longer interval results in a higher number of administered microspheres per GBq and in a lower activity per sphere as. This study aimed to demonstrate that, for a fixed Tumour Absorbed Dose (TAD), Tumour Control Probability (TCP) is higher when the decay interval is shorter (4 days vs. 8 days). In the second part of the study, we focused on fully perfused lesions, i.e. those showing matching perfused and radiological volumes, where calculating mean microsphere spatial density (ρ) is meaningful. We investigated which variable was associated with radiological response.METHODSWe retrospectively analysed lesion-by-lesion response at the best response time using the mRECIST criterion. Two chronologically sequential cohorts of patients were compared. Both cohorts were planned and treated with lobar administration, with exactly the same methodology, except for the post-calibration decay interval (Administration day: day 4 vs day 8). Infiltrative lesions and those with additional treatments post-radioembolization were excluded. To compare efficacy at the same TAD, we plotted TCP curves as a function of TAD and stratified TCP by lesion mass (M), using an arbitrary 50 g cut-off (equivalent to a 4.6 cm diameter). On fully perfused lesions, TCP was analyzed also as function of ρ and mass. We then conducted univariate ROC and multivariate analysed to assess response impact based on TAD, ρ, as, and M, grouping CR + PR (Objective Response, OR) versus SD + PD, as well as CR versus PR + SD + PD.RESULTSA total of 94 patients with 150 lesions were analyzed. TCP (for TAD up to 600 Gy) was significantly higher for the 59 lesions treated on Day 4 compared to the 91 lesions treated on Day 8, though the difference diminished at higher TAD values. In fully perfused lesions, TCP plateaued at 344 Gy and 160 Gy for lesions treated on Day 8 and Day 4 respectively. ROC analysis for fully perfused lesions showed poor AUC values for CR + PR versus SD + PD: 0.62, p = 0.01 for as, 0.63, p = 0.01 for TAD, and 0.60 p = 0.01 for M, with AUC for ρ being non-significant. When comparing CR versus PR + SD + PD classes, only M was significant, with a fair AUC value of 0.71, p = 0.01. Multivariate analysis showed that CR + PR was significantly associated only to as, with 79% higher response probability for administration on Day 4. When considering CR alone, significance was confirmed only for M, with an odd ratio of 0.19.DISCUSSIONOur findings on TCP confirmed our preliminary unpublished studies from a different lesion cohort assessed by two independent radiologists. Additionally, our results align with recent experimental histological studies on complete pathological necrosis (CPN) in explanted liver samples after neoadjuvant segmentectomy prior to liver transplantation. However, our data and the CPN findi","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"127 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144103733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic evaluation of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer.","authors":"Anna Julie Kjøl Høyvik,Monika Kvassheim,Li-Wei Ma,Elisabeth Wiig,Tiril Hillestad,Mona-Elisabeth Revheim,Rugile Liukaityte,Øyvind Bruland,Asta Juzeniene","doi":"10.1007/s00259-025-07330-y","DOIUrl":"https://doi.org/10.1007/s00259-025-07330-y","url":null,"abstract":"BACKGROUNDMetastatic castration-resistant prostate cancer (mCRPC) frequently leads to bone and soft tissue metastases, leading to poor prognosis. The beta-emitting radioligand [177Lu]Lu-PSMA-617 targets the prostate-specific membrane antigen (PSMA) and may be less efficient against micrometastatic disease. The alpha-emitting radioligand [212Pb]Pb-AB001 could offer enhanced treatment by delivering high energy over a short range. This study compared the efficacy of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer.METHODSBinding and internalisation of radioligands were evaluated in PC-3 PIP-luc cells. A mouse model was established by intracardiac injection of these cells. Treatments with 0.24‒1.0 MBq [212Pb]Pb-AB001 or 22‒66 MBq [177Lu]Lu-PSMA-617 were initiated 7 d post-cell inoculation. Metastatic burden was measured using bioluminescence imaging, and PSMA-targeted uptake was determined with [18F]F-PSMA-1007 µPET/µCT. Gamma-autoradiography evaluated [212Pb]Pb-AB001 distribution, and bone metastases were identified by radiography.RESULTSBoth radioligands displayed comparable in vitro binding. In vivo studies revealed metastatic formation in clinically relevant organs. µPET/µCT demonstrated increased [18F]F-PSMA-1007 uptake in metastases, matching the bioluminescence imaging results. Focal [212Pb]Pb-AB001 distribution in the metastatic xenograft indicated heterogeneously distributed micrometastases in the organs. A median survival up to 47 d was achieved with [212Pb]Pb-AB001, compared to 25 d for controls and 27 d for [177Lu]Lu-PSMA-617. An activity-dependent reduction in bone metastases was observed for [177Lu]Lu-PSMA-617, while no bone lesions were detected in [212Pb]Pb-AB001-treated mice.CONCLUSION[212Pb]Pb-AB001 showed significant efficacy against micrometastases and advantages over [177Lu]Lu-PSMA-617 in preventing or treating early bone metastases for the investigated injected activities. This implies clinical potential for treating mCRPC, including patients at risk of early metastatic disease, but further studies including dosimetry and toxicity analyses are required with regards to activity levels.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"31 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144103680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The brain-white adipose tissue axis may play a crucial role in diabetes mellitus: a metabolic network analysis using total-body PET/CT imaging","authors":"Lubing Sun, Yaping Wu, Junpeng Yang, Junting Liang, Panlong Li, Xuan Yu, Nan Meng, Tao Sun, Meiyun Wang, Chuanliang Chen","doi":"10.1007/s00259-025-07337-5","DOIUrl":"https://doi.org/10.1007/s00259-025-07337-5","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>This study aims to construct an individualized glucose metabolism network using total-body ¹⁸F-FDG PET imaging, which provides a comprehensive view of glucose metabolism across various organs, to explore the role of inter-organ interactions in Diabetes Mellitus (DM).</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>In this study, we constructed covariance metabolic networks using static total-body PET images, normalized by lean body mass, from 36 patients with DM (DM group) and 36 age- and sex-matched healthy controls (HC group). Differences in network properties between the DM and HC groups were evaluated at both group and individual levels. In addition, correlation analysis was performed to explore the relationship between network properties and baseline clinical data in the DM subjects.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>We observed that the same edges in the first three edges with the largest values were brain-subcutaneous adipose tissue (SAT) and brain-visceral adipose tissue (VAT) at both group and individual levels. There was a positive correlation between the brain-VAT and BMI and there was a negative correlation between the brain-SAT and age. The most perturbed organ was the brain at both group and individual levels, and there was a positive correlation between the strength of abnormality of brain and age.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>This study successfully used static total-body PET imaging to construct individualized glucose metabolism networks for patients with DM, identifying the brain-VAT and brain-SAT as the most significantly altered edge and the brain as the most affected organ. These findings provide novel insights into the role of the brain-white adipose tissue axis in glucose metabolism in DM.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"150 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144096867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}